Articles On Dimerix (ASX:DXB)

Title Source Codes Date
How Dimerix is now playing a crucial role in the global fight against COVID-19

The company’s participation in the CLARITY 2.0 study has taken on increased importance as India deals with a major COVID-19 outbreak. Biotech company Dimerix (ASX:DXB) is executing on a multi-channel development pathway for its proprietary...

Stockhead DXB 5 days ago
Dimerix (ASX:DXB) advances COVID-19 Phase 3 study, enrols multiple patients

Summary Drug discovery company developing new therapies, Dimerix, has enrolled multiple patients in REMAP-CAP study in Europe. In the ACE2 RAS study domain, subjects will be randomised to receive one RAS blockade strategy or control....

Kalkine Media DXB 2 weeks ago
COVID-19 study using Dimerix drug compound recruits patients in Europe

Special Report: The first 24 patients with COVID-19 pneumonia have been recruited into a multi-national clinical trial comparing Dimerix (ASX:DXB)’s DMX-200 drug candidate with other treatments. Over a year into the pandemic and yet another...

Stockhead DXB 2 weeks ago
Why the Dimerix (ASX:DXB) share price is rocketing higher

The Dimerix Ltd (ASX: DXB) share price has shot 6% higher to start the day after an update from the drug discovery company. Why is the Dimerix share price surging higher? Dimerix provided an update on its Phase 3 ACE2 renin angiotensin sys...

Motley Fool DXB 2 weeks ago
Five ASX penny stocks making a buzz today

Summary Eastern Iron’s share has shot up by a massive 45.5% to A$0.016 in today’s session. Kinetiko Energy’s share price has increased by 27.2% to A$0.14, breaking above its falling trendline on the charts. After Metallica Minerals re...

Kalkine Media DXB 2 weeks ago
5 ASX penny stocks delivering handsome return today

Source: Yuriy K, Shutterstock Summary Volt Resources’ share price is trading up by 26.67% to A$0.019 with a heavy volume of around 85 million shares. Suvo Strategic Minerals’ share price has been trending up since the beginning of the...

Kalkine Media DXB 3 weeks ago
How did Dimerix Limited (ASX:DXB) fare in Q3 FY21?

Source: Guschenkova, Shutterstock Summary Dimerix Limited made substantial progress on the operational front during the third quarter. The Company focussed on clinical trials advancement to offer treatments worldwide for patients havi...

Kalkine Media DXB 1 month ago
Here’s where Dimerix has a key advantage in the billion-dollar market for Diabetic Kidney Disease

The company is keeping its eye on the prize as it builds towards longer-term studies for its DMX-200 treatment solution to DKD. Biotech company Dimerix (ASX:DXB) has a number of irons in the fire as it moves through multiple Phase 3 trials...

Stockhead DXB 1 month ago
Market highlights and 5 ASX small caps to watch on Tuesday

Wall Street subdued, as bank stocks feel the heat Dow Jones rose slightly by 0.3%, while S&P 500 and NASDAQ fell by 0.09% and 0.6% respectively. Banks stocks were the main casualties, as Nomura and Credit Suisse both said they were faci...

Stockhead DXB 1 month ago
2 ASX healthcare penny stocks on the move - Dimerix and ECS Botanics

Source:Vintage Tone, Shutterstock Summary Dimerix has completed a study to confirm the nasogastric tube delivery of DMX-200 in COVID-19 patient admitted to ICU. ASX-listed medicinal cannabis player ECS Botanic enters into another medi...

Kalkine Media DXB 1 month ago
What’s latest with these 2 penny stocks- Dimerix (ASX:DXB) & DroneShield (ASX:DRO)

Source:ShutterstockProfessional,Shutterstock Summary Dimerix revealed that in-vitro study data demonstrate DMX-200 with endothelin A inhibitors shows greater potency and efficacy. A worldwide leader in drone security technology DroneS...

Kalkine Media DXB 1 month ago
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Stockhead DXB 1 month ago
Why the Dimerix (ASX:DXB) share price is up today

The Dimerix Ltd (ASX: DXB) share price is rising today after the biopharmaceutical company announced its involvement in a trial on COVID-19 therapies. Dimerix will be involved in the trial, named CLARITY 2.0, which has received approval fr...

Motley Fool DXB 2 months ago
Global CLARITY 2.0 study gets key approval from Indian regulators for clinical COVID-19 study, Dimerix shares jump

Special Report: Final clinical trial approval is expected by April for the study, in which Dimerix’s DMX-200 treatment plays a ... Read More The post Global CLARITY 2.0 study gets key approval from Indian regulators for clinical COVID-19 st...

Stockhead DXB 2 months ago
Here’s why Dimerix (ASX:DXB) shares are moving north today

Source: S_L ,Shutterstock Summary Dimerix Limited announced that the CLARITY 2.0 team obtained authorisation from the Central Independent Ethical Review Board. The Company has submitted dossiers for regulatory approvals in India for t...

Kalkine Media DXB 2 months ago
Dimerix planning longer study of DMX-200 to treat kidney disease

Special Report: Dimerix (ASX:DXB) is planning another study evaluating the use of its lead drug candidate to treat diabetic kidney ... Read More The post Dimerix planning longer study of DMX-200 to treat kidney disease appeared first on Sto...

Stockhead DXB 3 months ago
Dimerix has three ‘shots on goal’ next year

Special Report: Melbourne biotech company Dimerix (ASX:DXB) expects to receive readouts on three phase 3 studies in the near term ... Read More The post Dimerix has three ‘shots on goal’ next year appeared first on Stockhead.

Stockhead DXB 4 months ago
Dimerix announces a new COVID-19 study for DMX-200

Clinical-stage company Dimerix (ASX:DXB) has announced its lead candidate DMX-200 will enter a second clinical study in COVID-19 patients.

BiotechDispatch DXB 5 months ago
Second group of researchers to investigate efficacy of Dimerix drug candidate DMX-200 in treating COVID-19 patients

About 600 participants in India who have tested positive for COVID-19 will be enrolled in the randomised, double blind, placebo-controlled ... Read More The post Second group of researchers to investigate efficacy of Dimerix drug candidate...

Stockhead DXB 5 months ago
Why the Dimerix (ASX:DXB) share price is surging 6% higher today

The Dimerix Ltd (ASX: DXB) share price lifted higher today after the company announced the start of its second clinical study on lead drug candidate, DMX-200. At the time of writing, the Dimerix share price is up 6.1% at 26 cents. What’s d...

Motley Fool DXB 5 months ago
Why HeraMed (ASX:HMD) and Dimerix (ASX:DXB) are trending?

Summary HeraMED’s partnership with eCare21 aims to fast-track awareness of HeraCARE and HeraBEAT across the US. Dimerix drug compound DMX-200 is set to be tested for COVID-19-induced ARDS in the global study. Dimerix is confident that...

Kalkine Media DXB 5 months ago
Global study will test Dimerix drug compound DMX-200 as COVID-19 treatment

Special Report: Melbourne biotech company Dimerix (ASX:DXB) is working with independent researchers to ship its lead drug candidate DMX-200 to ... Read More The post Global study will test Dimerix drug compound DMX-200 as COVID-19 treatment...

Stockhead DXB 6 months ago
Dimerix’s DMX-700 drug candidate has enormous potential

Special Report: Dimerix is developing a potential treatment for constructive obstructive pulmonary disease (COPD), the fourth-leading cause of death worldwide. ... Read More The post Dimerix’s DMX-700 drug candidate has enormous potential a...

Stockhead DXB 6 months ago
Dimerix shares up after analysis on DMX-200 diabetic kidney disease trial results

Melbourne biotech release analysis of study that sent share price crashing last month Study showed drug candidate did seem to ... Read More The post Dimerix shares up after analysis on DMX-200 diabetic kidney disease trial results appeared...

Stockhead DXB 6 months ago
Dimerix updates on the development of DMX-200 for kidney disease

Dimerix (ASX:DXB) says it has navigated another important step in the development of its lead compound DMX-200 for the treatment of kidney disease.

BiotechDispatch DXB 6 months ago
Dimerix Share Price Rises 9% on Positive Results (ASX:DXB)

Shares of Melbourne-based biotechnology company Dimerix Ltd [ASX:DXB] have gained 9% today, to trade at 32 cents at the time of writing. The DXB share price rose on the back of encouraging results that will support... The post Dimerix Share...

MoneyMorning DXB 7 months ago
Dimerix updates on latest kidney disease trial of DMX-200

Melbourne-based clinical-stage biopharmaceutical company Dimerix (ASX:DSB) has updated on clinical trials of its drug candidate DMX-200 for kidney diseases.

BiotechDispatch DXB 7 months ago
Dimerix Share Price plummets despite positive study results: More to it than meets the eye?

Summary ASX listed clinical-stage healthcare company Dimerix Limited announced positive results in Phase 2 clinical trial of DMX-200 in diabetic kidney disease patients. Following the announcement, Dimerix Limited’s share price fell sha...

Kalkine Media DXB 7 months ago
Closing Bell: Today’s biggest small cap movers on the ASX

A quick wrap of the ASX’s key winners and losers on Monday, September 14. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow made potentially market-moving announcements during the day.   WINNERS Code Na...

Stockhead DXB 7 months ago
Dimerix to move forward with DMX-200 after phase 2 clinical trial

Special Report: Dimerix plans to further explore the potential of DMX-200 to treat kidney diseases following the completion of a positive and informative phase-2 trial. Dimerix (ASX:DXB) says it will progress with research on its chemokine...

Stockhead DXB 7 months ago
Why the Dimerix (ASX:DXB) share price has plunged 63% today

The Dimerix Ltd (ASX: DXB) share price has plummeted 63.51% today to 27 cents. This came after the drug company reported the results of its phase 2 study of DMX-200 in patients with diabetic kidney disease. Why has the Dimerex share price...

Motley Fool DXB 7 months ago
10 at 10: These ASX stocks are the stand outs this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead DXB 7 months ago
Scopo’s Health Powerplays: Show me the (grant) money

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week We’re coming...

Stockhead DXB 8 months ago
Dimerix Share Price Up on Funding News (ASX:DXB)

Melbourne-based biotech company Dimerix Ltd [ASX:DXB] got a shot in the arm recently after being awarded $1 million from the Australian government’s Medical Research Future Fund. This has pushed the DXB share price up 7.14% to trade at 75 c...

MoneyMorning DXB 8 months ago
3 ASX shares that could make you rich

Right now investors have a range of areas to choose great ASX shares for growth. On one hand we see radical changes in short term credit with the buy now, pay later companies led by Afterpay Ltd (ASX: APT). On the other hand, changes in th...

Motley Fool DXB 9 months ago
ASX Biotechs Surfing The Covid Story

By Tim Boreham, Editor, The New Criterion The ASX biotechs surfing the COVID-19 story Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life sciences stocks across the d...

FNArena DXB 9 months ago
ASX biotech stocks benefiting from the COVID-19 story

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with...

SmallCaps DXB 9 months ago
Scopo’s powerplays: Hemp hippies and wellness wonderlands

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With quart...

Stockhead DXB 9 months ago
Two Stocks That Were Up Following Major Announcements - Mesoblast and Dimerix

Summary Mesoblast disclosed that the Phase 3 clinical trial of Remestemcel-L is anticipated to complete recruitment in September 2020 in the US. At the end of the quarter ended June 2020, Mesoblast had nearly US$129.3 million cash on ha...

Kalkine Media DXB 9 months ago
Dimerix reports positive results from DMX-200 trial

Melbourne-based biopharmaceutical company Dimerix (ASX:DXB) has reported positive results from the clinical trial of its drug candidate DMX-200.

BiotechDispatch DXB 9 months ago
Closing Bell: Today’s biggest small cap movers on the ASX

A quick wrap of the ASX’s key winners and losers on Wednesday, July 29. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 529 stocks rose, 801 declined and...

Stockhead DXB 9 months ago
Dimerix unveils ‘tremendous’ top-line results for lead drug in treating rare kidney disorder

Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often le...

SmallCaps DXB 9 months ago
Dimerix shares climb 40pc on FSGS drug trial success

Dimerix’s (ASX: DXB) phase-two trial for focal segmental glomerulosclerosis (FSGS) has met both primary and secondary endpoints, with 86 per cent of patients showing a response to the drug DMX-200 versus placebo. This morning’s news drove t...

Stockhead DXB 9 months ago
10 at 10: These ASX stocks are pollinating this morning

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead DXB 9 months ago
Dimerix’s choice: do they partner or go it alone?

Special Report: With results from the first of three clinical trials set to come in this year, shareholders are asking: is it smart for Dimerix to licence its drug candidates for the final stages, or go it alone?   As biotech Dimerix (ASX:D...

Stockhead DXB 9 months ago
Dimerix’s choice: do they partner or go it alone?

Special Report: With results from the first of three clinical trials set to come in this year, shareholders are asking: is it smart for Dimerix to licence its drug candidates for the final stages, or go it alone?   As biotech Dimerix (ASX:D...

Stockhead DXB 9 months ago
Capital raisings: Investors upped the ante in June, resources took top spot

In June, ASX-listed companies of all sizes continued to raise capital but the small-cap sector was particularly busy. Stocks with market capitalisations of under $100m at the time of the deal raised $274m in the last month. This is triple M...

Stockhead DXB 10 months ago
Health Kick: This drug developer is up 200pc following inclusion in a COVID-19 related trial

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim catches up with CEO and MD of Dimerix, Nina Webster. Dim...

Stockhead DXB 10 months ago
Dimerix completes placement to support REMAP-CAP study

Clinical-stage biopharmaceutical company Dimerix (ASX:DXB) has announced the placement of 16,222,580 fully paid ordinary shares to institutional and sophisticated investors at a price of $0.36 per share to raise $5.8 million before...

BiotechDispatch DXB 10 months ago
Institutions back hotshot Dimerix for COVID-19 study

Special Report: Biotech Dimerix wins over institutional investors as it prepares for a global Phase 3 COVID-19 trial. Hotshot biotech Dimerix (ASX:DXB) is finally on the radar of institutional investors, who bought in for the first time via...

Stockhead DXB 10 months ago